Limits...
Appropriateness criteria of FDG PET/CT in oncology.

Agrawal A, Rangarajan V - Indian J Radiol Imaging (2015 Apr-Jun)

Bottom Line: In this article, we have incorporated the various indications for (18)FDG PET/CT in oncology based on available evidence and current guidelines.Growing body of evidence for use of (18)FDG PET/CT in select tumors is also discussed.This article attempts to give the reader an overview of the appropriateness of using (18)F-FDG PET/CT in various malignancies.

View Article: PubMed Central - PubMed

Affiliation: Department of Nuclear Medicine and Molecular Imaging, Tata Memorial Hospital, Mumbai, Maharashtra, India.

ABSTRACT
(18)Fluorine-2-fluoro-2-Deoxy-d-glucose ((18)F-FDG) positron emission tomography/computerized tomography (PET/CT) is a well-established functional imaging method widely used in oncology. In this article, we have incorporated the various indications for (18)FDG PET/CT in oncology based on available evidence and current guidelines. Growing body of evidence for use of (18)FDG PET/CT in select tumors is also discussed. This article attempts to give the reader an overview of the appropriateness of using (18)F-FDG PET/CT in various malignancies.

No MeSH data available.


Related in: MedlinePlus

A 65-year-old male, a case of NHL. (A) The pretreatment PET MIP image shows extensive nodal and extranodal involvement (B) PET scan done after completion of six cycles of chemotherapy (post-treatment response assessment) shows complete metabolic resolution of disease
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4419439&req=5

Figure 2: A 65-year-old male, a case of NHL. (A) The pretreatment PET MIP image shows extensive nodal and extranodal involvement (B) PET scan done after completion of six cycles of chemotherapy (post-treatment response assessment) shows complete metabolic resolution of disease

Mentions: FDG PET leads to upstaging of disease in about 30% of cases at initial staging[4] [Figure 1]. The sensitivity and specificity of PET/CT is higher as compared to CECT for detection of nodal as well as extranodal disease.[56] The International Harmonization Project recommends the use of a baseline FDG PET in HL and aggressive NHL.[7] There is no added advantage of adding CECT in staging or combining it with PET/CT.[8] This only increases the cost and radiation burden. It is also helpful in management of residual masses that are seen after completion of therapy by correctly predicting the presence or absence of viable disease [Figure 2]. CECT is the imaging modality of choice in staging all low-grade lymphomas,[9] except in MALT where FDG PET/CT may have a potential role.[10]


Appropriateness criteria of FDG PET/CT in oncology.

Agrawal A, Rangarajan V - Indian J Radiol Imaging (2015 Apr-Jun)

A 65-year-old male, a case of NHL. (A) The pretreatment PET MIP image shows extensive nodal and extranodal involvement (B) PET scan done after completion of six cycles of chemotherapy (post-treatment response assessment) shows complete metabolic resolution of disease
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4419439&req=5

Figure 2: A 65-year-old male, a case of NHL. (A) The pretreatment PET MIP image shows extensive nodal and extranodal involvement (B) PET scan done after completion of six cycles of chemotherapy (post-treatment response assessment) shows complete metabolic resolution of disease
Mentions: FDG PET leads to upstaging of disease in about 30% of cases at initial staging[4] [Figure 1]. The sensitivity and specificity of PET/CT is higher as compared to CECT for detection of nodal as well as extranodal disease.[56] The International Harmonization Project recommends the use of a baseline FDG PET in HL and aggressive NHL.[7] There is no added advantage of adding CECT in staging or combining it with PET/CT.[8] This only increases the cost and radiation burden. It is also helpful in management of residual masses that are seen after completion of therapy by correctly predicting the presence or absence of viable disease [Figure 2]. CECT is the imaging modality of choice in staging all low-grade lymphomas,[9] except in MALT where FDG PET/CT may have a potential role.[10]

Bottom Line: In this article, we have incorporated the various indications for (18)FDG PET/CT in oncology based on available evidence and current guidelines.Growing body of evidence for use of (18)FDG PET/CT in select tumors is also discussed.This article attempts to give the reader an overview of the appropriateness of using (18)F-FDG PET/CT in various malignancies.

View Article: PubMed Central - PubMed

Affiliation: Department of Nuclear Medicine and Molecular Imaging, Tata Memorial Hospital, Mumbai, Maharashtra, India.

ABSTRACT
(18)Fluorine-2-fluoro-2-Deoxy-d-glucose ((18)F-FDG) positron emission tomography/computerized tomography (PET/CT) is a well-established functional imaging method widely used in oncology. In this article, we have incorporated the various indications for (18)FDG PET/CT in oncology based on available evidence and current guidelines. Growing body of evidence for use of (18)FDG PET/CT in select tumors is also discussed. This article attempts to give the reader an overview of the appropriateness of using (18)F-FDG PET/CT in various malignancies.

No MeSH data available.


Related in: MedlinePlus